1. Homepage
  2. Equities
  3. China
  4. Shenzhen Stock Exchange
  5. Huadong Medicine Co., Ltd
  6. Summary
    000963   CNE0000011S1

HUADONG MEDICINE CO., LTD

(000963)
  Report
End-of-day quote Shenzhen Stock Exchange  -  2022-08-15
41.95 CNY   -1.06%
08/09Huadong Medicine Buys 60% of Nanomaterials Maker Wuhu Huaren For $57 Million
MT
08/09Huadong Medicine Co., Ltd Reports Earnings Results for the Half Year Ended June 30, 2022
CI
06/02Huadong Medicine Co., Ltd Approves Board Appointments
CI
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Shenzhen Stock Exchange
08/10/2022 08/11/2022 08/12/2022 08/15/2022 08/16/2022 Date
44.74 44.39 43.08 42.4 41.95 Last
19145400 15630400 14905270 20689950 9802856 Volume
+1.80% -0.78% -2.95% -1.58% -1.06% Change
Estimated financial data (e)
Sales 2022 38 384 M 5 655 M 5 655 M
Net income 2022 2 810 M 414 M 414 M
Net cash position 2022 3 143 M 463 M 463 M
P/E ratio 2022 26,1x
Yield 2022 0,75%
Sales 2023 42 066 M 6 197 M 6 197 M
Net income 2023 3 395 M 500 M 500 M
Net cash position 2023 4 702 M 693 M 693 M
P/E ratio 2023 21,6x
Yield 2023 0,93%
Capitalization 73 405 M 10 814 M 10 814 M
EV / Sales 2022 1,83x
EV / Sales 2023 1,63x
Nbr of Employees 12 427
Free-Float 41,8%
More Financials
Company
Huadong Medicine Co., Ltd. specializes in the development, manufacture and marketing of medical products and vaccines. The products are intended primarily for the treatment of tumors, immune disorders, endocrine disorders, orthopedic and traumatological disorders, digestive system diseases and viral diseases. 
Sector
Pharmaceuticals
Calendar
08/31 | 02:00amShareholder meeting
More about the company
Ratings of Huadong Medicine Co., Ltd
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C+
More Ratings
All news about HUADONG MEDICINE CO., LTD
08/09Huadong Medicine Buys 60% of Nanomaterials Maker Wuhu Huaren For $57 Million
MT
08/09Huadong Medicine Co., Ltd Reports Earnings Results for the Half Year Ended June 30, 202..
CI
06/02Huadong Medicine Co., Ltd Approves Board Appointments
CI
06/02Huadong Medicine Co., Ltd Approves Cash Dividend on A Shares for the Year 2021, Payable..
CI
04/28Huadong Medicine's 2021 Profit Plunges 18% Despite Higher Sales; Shares Jump 5%
MT
04/28Huadong Medicine Co., Ltd Proposes Final Cash Dividend for the Year 2021
CI
04/27Huadong Medicine Co., Ltd Reports Earnings Results for the First Quarter Ended March 31..
CI
04/27Huadong Medicine Co., Ltd Reports Earnings Results for the Full Year Ended December 31,..
CI
04/27Ashvattha Therapeutics, Inc. announced that it has received $69 million in funding from..
CI
02/28Huadong Medicine Buys 35% Stake in German Cancer Drug Firm Heidelberg for $117.5 Millio..
MT
02/28Heidelberg Pharma Grants Up to $930 Million Drug Development License to China's Huadong..
MT
02/27Huadong Medicine Co., Ltd agreed to acquire 9% stake in Heidelberg Pharma AG from dievi..
CI
02/23Huadong Medicine Bags Exclusive Rights for US-Based Kiniksa's Autoimmune Drugs
MT
02/09AKSO and Huadong Medicine Announce Strategic Collaboration to Develop and Commercialize..
BU
2021HUADONG MEDICINE CO., LTD : 3rd quarter report
CO
More news
News in other languages on HUADONG MEDICINE CO., LTD
08/09Huadong Medicine achète 60% du fabricant de nanomatériaux Wuhu Huaren pour 57 millions ..
08/09Huadong Medicine Co., Ltd. annonce ses résultats pour le semestre clos le 30 juin 2022
06/02Huadong Medicine Co., Ltd approuve les nominations au conseil d'administration
06/02Huadong Medicine Co., Ltd approuve le dividende en espèces pour l'année 2021
04/28Le bénéfice de Huadong Medicine en 2021 plonge de 18% malgré la hausse des ventes ; les..
More news
Chart HUADONG MEDICINE CO., LTD
Duration : Period :
Huadong Medicine Co., Ltd Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends HUADONG MEDICINE CO., LTD
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 9
Last Close Price 41,95 CNY
Average target price 45,05 CNY
Spread / Average Target 7,39%
EPS Revisions
Managers and Directors
Liang Lü General Manager & Director
Hong Lan Ma Chief Financial Officer
Bang Liang Li Chairman
Xin Hua Bai Chairman-Supervisory Board
Lan Yang Independent Director